In the clearest sign yet of the US Food and Drug Administration’s growing acceptance of so-called virtual drug good manufacturing practice inspections during the coronavirus pandemic, an FDA official said 2 November that the agency is developing industry guidance on the topic.
The FDA has lagged behind other regulatory authorities including the European Medicines Agency and the UK Medicines and Healthcare products Regulatory Agency in adopting remote video virtual inspection approaches. (Also see "How The European Medicines Agency Inspected Thermo Fisher’s Florida Plant Without Leaving Europe" - Pink Sheet, 21 July, 2020